Telehealth companies are taking advantage of the growing demand for weight loss drugs and are not only helping patients with obesity but also influencing the medical community’s understanding of the condition.
Ro, a major player in the telehealth industry, recently introduced a new questionnaire aimed at measuring “food noise,” a term commonly used by individuals with obesity to describe constant and overwhelming thoughts about food. Developed by academic researchers with funding from Ro, the scale is designed to assess whether treatments can reduce patients’ level of food noise. This concept has gained popularity in recent years with the emergence of new GLP-1 drugs like Wegovy and Zepbound.
Ro is utilizing the scale to monitor patients’ progress during treatment and has also made it available to pharmaceutical companies for use in clinical trials.
The integration of telehealth companies into the weight loss drug market is reshaping how obesity is viewed and treated. By focusing on concepts like food noise and actively participating in the development of assessment tools, these companies are not only providing innovative solutions for patients but also contributing to advancements in obesity research.
As the demand for telehealth services continues to rise, it is clear that these companies will play a significant role in shaping the future of obesity treatment and management. With their ability to reach a wider audience and offer personalized care, telehealth companies are revolutionizing the way healthcare professionals approach weight loss and obesity.
